Status:
UNKNOWN
Fluorescent-labeled IgG for Liver Tumor Detection
Lead Sponsor:
Chinese Academy of Sciences
Conditions:
Liver Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma). Th...
Eligibility Criteria
Inclusion
- Patients who have been diagnosed with liver tumor.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A/B.
- The expected lifetime is longer than 6 months.
- Approved to sign the informed consent.
Exclusion
- Enrolled in other trials in the past 3 months.
- Metastatic lesions were found.
- Undesirable function of heart, lung, kidney, or any other organs.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
Key Trial Info
Start Date :
May 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05394246
Start Date
May 20 2022
End Date
June 30 2025
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China